INTRODUCTION: The aim of the investigation was to determine pleiotropic cytokine IL-6 concentrations in serum and CSF of MS patients, with regard to clinical circumstances. MATERIAL AND METHODS: The study covered 27 MS patients: 23-51 years old; in the 2-7 clinical stage according to Kurtzke's Scale; mean 3.6 +/- 1.8; disease duration time ranged between 2-22 years. Serum and CSF interleukin-6 were determined by the use of commercial ELISA kits. RESULTS: Increase of Il-6 in serum of MS patients was found (12.1 +/- 1.8 pg/ml) in comparison to the control group (6.6 +/- 4.5 pg/ml) (p = 0.03). Concentration of IL-6 in CSF of MS patients was 13.4 +/- 1.77 pg/ml and in the majority of patients it was higher than in the serum. The highest mean of IL-6 concentrations in serum and CSF have been found in patients at the longer disease duration time, although there were not statistically significant. We have found some degree of dependence between serum IL-6 concentration and the level of disability in Kurtzke's scale. CONCLUSIONS: IL-6 participation in the basic MS immune processes is confirmed by its elevated concentration in serum and CSF, its relation to disease severity with the more expressed rise in cerebrospinal fluid.
INTRODUCTION: The aim of the investigation was to determine pleiotropic cytokine IL-6 concentrations in serum and CSF of MSpatients, with regard to clinical circumstances. MATERIAL AND METHODS: The study covered 27 MSpatients: 23-51 years old; in the 2-7 clinical stage according to Kurtzke's Scale; mean 3.6 +/- 1.8; disease duration time ranged between 2-22 years. Serum and CSFinterleukin-6 were determined by the use of commercial ELISA kits. RESULTS: Increase of Il-6 in serum of MSpatients was found (12.1 +/- 1.8 pg/ml) in comparison to the control group (6.6 +/- 4.5 pg/ml) (p = 0.03). Concentration of IL-6 in CSF of MSpatients was 13.4 +/- 1.77 pg/ml and in the majority of patients it was higher than in the serum. The highest mean of IL-6 concentrations in serum and CSF have been found in patients at the longer disease duration time, although there were not statistically significant. We have found some degree of dependence between serum IL-6 concentration and the level of disability in Kurtzke's scale. CONCLUSIONS:IL-6 participation in the basic MS immune processes is confirmed by its elevated concentration in serum and CSF, its relation to disease severity with the more expressed rise in cerebrospinal fluid.
Authors: Marko Petržalka; Eva Meluzínová; Jana Libertínová; Hana Mojžišová; Jitka Hanzalová; Petra Ročková; Martin Elišák; Silvia Kmetonyová; Jan Šanda; Ondřej Sobek; Petr Marusič Journal: PLoS One Date: 2022-06-27 Impact factor: 3.752
Authors: Jose Enrique de la Rubia Ortí; Jose Luis Platero; María Benlloch; Lorena Franco-Martinez; Asta Tvarijonaviciute; Jesús Escribá-Alepuz; Sandra Sancho-Castillo Journal: Biomolecules Date: 2021-04-21
Authors: Katherine G Ravelli; Graziella D Santos; Nilton B Dos Santos; Carolina D Munhoz; Deborah Azzi-Nogueira; Ana Carolina Campos; Rosana L Pagano; Luiz R Britto; Marina S Hernandes Journal: Transl Neurosci Date: 2019-03-26 Impact factor: 1.757
Authors: Jun Yan; Jia Liu; Clement Yihao Lin; Peter A Csurhes; Michael P Pender; Pamela A McCombe; Judith M Greer Journal: Int J Mol Sci Date: 2012-10-22 Impact factor: 5.923